Print page     Email page

Management

show all hide all

Rajesh C. Shrotriya, MD

Chairman, Chief Executive Officer and President

In September 2000, Dr. Shrotriya joined the Company as President and Chief Operating Officer and in August 2002, he was appointed Chief Executive Officer. In this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc.

Previously, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.

Dr. Shrotriya is a 2011 Ernst & Young Orange County Region Entrepreneur of the Year® award winner. Dr. Shrotriya was specifically cited for his turn-around of Spectrum. The Ernst & Young LLP award program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Dr. Shrotriya was chosen from 15 finalists by a panel of independent judges.

Steven M. Fruchtman, MD

Senior Vice President & Chief Medical Officer

Dr. Fruchtman joined Spectrum in February 2011 to head clinical development. Previously, Dr. Fruchtman was with Allos Therapeutics, where he was involved with the development of pralatrexate (Folotyn) for hematologic and oncologic indications. Prior to joining Allos, Dr. Fruchtman was Senior Director of US Clinical Development and Medical Affairs for Novartis Pharmaceuticals. At Novartis, he was responsible for the development of LBH589 (Panobinostat) for hematologic and oncologic indications and was responsible for registration trials in the United States for several indications; lead development of post marketing trials for Proleukin (IL-2) in renal cell carcinoma and melanoma; and lead development of RAD001 (Afinitor) for hematological indications. Prior to his tenure at Novartis, he was the Medical Director of Hematology and Oncology Therapeutics and Clinical Affairs at Ortho Biotech Products (OBI), L.P., a division of Johnson and Johnson Pharmaceuticals. At OBI, he was responsible for the clinical development of DOXIL® Phase 4 trials in hematological malignancies, (multiple myeloma and non-Hodgkin's lymphoma), Velcade and DOXIL® for 2nd line multiple myeloma, Zarnestra® (tipifarnib) Phase 1 and 2 trials in myelodysplastic syndrome (MDS) and acute myeloid leukemia, Procrit® for MDS, and Yondelis® (trabectedin) trials in soft tissue sarcoma and ovarian cancer. Prior to his career in industry, Dr. Fruchtman enjoyed a successful academic career at Mount Sinai Hospital and Medical School in New York, where he was Chief of the Stem Cell Transplantation Program.

Dr. Fruchtman has served as an external reviewer for the New England Journal of Medicine, Mayo Clinic Proceedings, Experimental Hematology, European Journal of Hematology, Leukemia, and served on the editorial board of The Mount Sinai Journal of Medicine. Dr. Fruchtman is an author of more than 170 lectures, presentations, books, chapters, and abstracts. Dr. Fruchtman received his Bachelor of Arts with Honors from Cornell University, and his MD from New York Medical College.

Brett L. Scott, CPA

Senior Vice President, Acting Chief Financial Officer

Mr. Scott, a Certified Public Accountant, has served as CFO for a variety of publicly traded companies. Most recently he was CFO at BIOLASE Technology, Inc. (NASDAQ: BLTI), an Irvine, California-based medical device company that designs, manufactures, and markets advanced dental, cosmetic, and surgical lasers and related products worldwide.

Prior to BIOLASE, Mr. Scott was CFO for North American Scientific, an Irvine, California-based medical device company that manufactures, markets and sells products used primarily in the treatment of prostate and breast cancer. The prostate cancer business was sold to BEST Medical in April 2009 and the breast cancer business was sold to Portola Medical in May 2009. Prior to North American Scientific, Mr. Scott was CFO for Irvine, California-based Alsius Corporation. At Alsius, Mr. Scott managed the initial IPO process and was a key member of the negotiating team during the resulting merger with Ithaka Acquisition Company, a specified purpose acquisition company. From September 2001 to March 2005, Mr. Scott was CFO at Irvine, California-based Irvine Biomedical, which was acquired by St. Jude Medical, Inc. in 2004 and designs, develops, manufactures and markets electrophysiology products for the minimally-invasive diagnosis and treatment of cardiac arrhythmias.

From July 2001 to December 2002, Mr. Scott was CFO and a member of the Board of Directors of Irvine, California-based Pain Concepts Inc. that sold its product line to Stryker Medical Inc. in October 2003. He has also been CFO at Cardiac Science and Neuro Navigational Corporation.

Mr. Scott has a Bachelor of Science degree in business administration from the University of Southern California.

James E. Shields

Senior Vice President, Chief Commercial Officer

Spectrum Pharmaceuticals

Mr. Shields' experience spans Fortune 500, biotechnology, as well as small-to-mid-size companies with an emphasis on establishing and leading successful commercial sales operations. Mr. Shields' oncology sales experience includes serving as the Vice President of Sales for Oncology and Injectable Products for MGI Pharmaceuticals, and Vice President of Sales and Marketing of Oncology for Supergen.

Mr. Shields also held positions of increasing responsibility with several pharmaceutical companies, including Centocor, Bristol-Myers Squibb, ICI, and Stuart Pharmaceuticals. Mr. Shields was most recently with Teva Pharmaceutical Industries Limited.

Mr. Shields earned his Bachelor's Degree from the University of Kentucky.

Rick Gonzalez

Senior Vice President, Commerical

Rick Gonzalez joined Spectrum in March 2008 and has had increasing responsibilities leading teams within Spectrum's Commercial group. Mr. Gonzalez is responsible for designing and leading all commercial strategies for marketed and late-stage products, including Sales, Commercial Operations, Business Solutions and Brand Management. Mr. Gonzalez reports directly to Jim Shields.

Prior to joining Spectrum, Mr. Gonzalez was a founding member of the Abraxis Oncology commercial team, where he held positions in sales management, marketing and account management. Mr. Gonzalez has 20 years of experience in the pharmaceutical industry of which 14 have been in specialty markets, including Hematology/Oncology. Prior companies include GlaxoSmithKline, Roche Laboratories, Ligand Pharmaceuticals and Genzyme.

Mr. Gonzalez earned his Bachelor of Science in Business Logistics from Penn State University.